

**Sublocade**  
**Effective 04/01/2022**

<b>Plan</b>	<input type="checkbox"/> MassHealth <input checked="" type="checkbox"/> Commercial/Exchange	<b>Program Type</b>	<input checked="" type="checkbox"/> Prior Authorization
<b>Benefit</b>	<input type="checkbox"/> Pharmacy Benefit <input checked="" type="checkbox"/> Medical Benefit (NLX)		<input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
<b>Specialty Limitations</b>	N/A		
<b>Contact Information</b>	<b>Specialty Medications</b>		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	<b>Non-Specialty Medications</b>		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	<b>Medical Specialty Medications (NLX)</b>		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
<b>Exceptions</b>	N/A		

### Overview

**Sublocade** is an extended-release injection for treatment of moderate to severe opioid use disorder in patients who have initiated treatment with 8 to 24 mg of a transmucosal buprenorphine-containing product, followed by dose adjustment for a minimum of 7 days.

### Coverage Guidelines

Approval of Sublocade will be granted if the member meets the following drug specific criteria:

#### Sublocade

1. Member has diagnosis of moderate to severe opioid use disorder **AND**
2. Member has been stabilized on  $\leq 24$  mg buprenorphine per day for at least seven days; **AND**
3. Provider has submitted medical necessity for the use of the extended-release injection formulation due to one of the following:
  - a. The member has been stable on transmucosal buprenorphine therapy delivering an equivalent of 8 to 24 mg of daily buprenorphine for at least seven days **AND** significant patient safety concerns that would make having transmucosal buprenorphine containing products in the home not ideal **OR**
  - b. The member has been stable on transmucosal buprenorphine therapy delivering an equivalent of 8 to 24 mg of daily buprenorphine for at least seven days **AND** significant concerns with diversion of transmucosal buprenorphine-containing buprenorphine products exists

### Continuation of Therapy

#### Sublocade

Requests for continuation of therapy will require all the following documentation:



1. The member will not receive supplemental transmucosal buprenorphine-containing products while receiving Sublocade (buprenorphine extended-release)

### Limitations

1. Approvals will be granted for **Sublocade** for 6 months.

### Appendix

Dosing equivalent of 8mg per day or less of transmucosal buprenorphine products

DRUG	DOSE
Buprenorphine	8mg or less
Suboxone [or generic equivalent]	8/2 mg or less
Bunavail	4.2/0.7 mg or less
Zubsolv	5.7/1.4 mg or less

### References

1. Sublocade (buprenorphine extended-release) [prescribing information]. North Chesterfield, VA: Indivior Inc; March 2018
2. Buprenorphine sublingual tablets [prescribing information]. Morgantown, WV: Mylan; February 2018.
3. Probuphine (buprenorphine) implant for subdermal administration [prescribing information]. Princeton, NJ: Braeburn Pharmaceuticals, Inc.; February 2018
4. Suboxone sublingual film (buprenorphine/naloxone) [prescribing information]. Richmond, VA: Indivior; February 2018.
5. Zubsolv (buprenorphine/naloxone) [prescribing information]. Morristown, NJ: Orexo US; February 2018.
6. Bunavail (buprenorphine/naloxone) [prescribing information]. Raleigh, NC: BioDelivery Sciences International Inc; February 2018

### Review History

02/20/19 – Reviewed

11/18/20 – Reviewed P&T

03/16/2022 – Reviewed and Updated for March P&T; removed Probuphine from program as drug is no longer available. Effective 04/01/2022.

### Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.